Search - tctmd.com

Displaying 381 - 400 of 1162

Sort: Relevancy | Date

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

News Conference News ESC 2022

Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms

Yael L. Maxwell

August 31, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

News Conference News ESC 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

August 27, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection Open With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.” configuration options With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.”

News Conference News ESC 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection

August 26, 2022

Enoxaparin Tops Aspirin for Preventing VTE After Hip or Knee Arthroplasty

News Daily News

Enoxaparin Tops Aspirin for Preventing VTE After Hip or Knee Arthroplasty

August 25, 2022

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

News Daily News

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

August 23, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

News Daily News

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Michael O'Riordan

August 16, 2022

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

Acute MI, Stroke Risks Rise in the Months After Gout Flares

News Daily News

Acute MI, Stroke Risks Rise in the Months After Gout Flares

August 02, 2022

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

CV Risk Factor Control Cuts Post-op Nursing Home Transfer for Black Americans

News Daily News

CV Risk Factor Control Cuts Post-op Nursing Home Transfer for Black Americans

Yael L. Maxwell

July 22, 2022

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

News Daily News

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

July 20, 2022

Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained

News Daily News

Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained

Yael L. Maxwell

July 15, 2022

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

News Daily News

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

Michael O'Riordan

July 11, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.